Combined therapy of an established, highly aggressive breast cancer in mice with paclitaxel and a unique DNA-based cell vaccine

Amla Chopra, Tae Sung Kim, InSug O-Sullivan, Don Martinez, Edward P. Cohen

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Here, we describe the enhanced benefits of treating a highly aggressive breast cancer in mice with a combination of paclitaxel and immunization with a unique DNA-based cell vaccine. An adenocarcinoma was isolated from a spontaneous neoplasm that arose in the mammary gland of a C3H/He mouse (H-2k) (SB5b cells). The vaccine was prepared by transfer of genomic DNA-fragments (25 kb) from the breast cancer cells into a mouse fibroblast cell line (LM), modified to enhance its immunogenic properties. As the transferred DNA is integrated, and replicated as the recipient cells divide, the vaccine could be prepared from relatively small numbers of cancer cells (107 = 4 mm tumor). SB5b cells were injected into the mammary fat pad of naïve C3H/He mice, which are highly susceptible to the growth of the cancer cells. When the tumors reached ∼3 mm, the mice were injected s.c. with a noncurative dose of paclitaxel. Six days later, when immune competence returned, the mice received the first of 3 weekly s.c. injections of the vaccine. The combined therapy induced robust cellular immunity to the breast cancer, mediated by CD8+ and NK/LAK cells, which resulted in prolonged survival. The immunity was specific, as immunization with a vaccine prepared by transfer of DNA from B16 melanoma cells into the fibroblasts failed to induce immunity to the breast cancer. This type of vaccine raises the possibility that an analogous strategy could be used in the treatment of breast cancer patients at an early stage of the disease.

Original languageEnglish
Pages (from-to)2888-2898
Number of pages11
JournalInternational Journal of Cancer
Volume118
Issue number11
DOIs
Publication statusPublished - 2006 Jun 1

Fingerprint

Paclitaxel
Vaccines
Breast Neoplasms
DNA
Inbred C3H Mouse
Neoplasms
Therapeutics
Immunity
Immunization
Fibroblasts
Lymphokine-Activated Killer Cells
Experimental Melanomas
Human Mammary Glands
Cellular Immunity
Natural Killer Cells
Mental Competency
Adipose Tissue
Adenocarcinoma
Breast
Cell Count

Keywords

  • Breast cancer
  • DNA-based cell vaccine
  • Immunotherapy
  • Preclinical

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Combined therapy of an established, highly aggressive breast cancer in mice with paclitaxel and a unique DNA-based cell vaccine. / Chopra, Amla; Kim, Tae Sung; O-Sullivan, InSug; Martinez, Don; Cohen, Edward P.

In: International Journal of Cancer, Vol. 118, No. 11, 01.06.2006, p. 2888-2898.

Research output: Contribution to journalArticle

Chopra, Amla ; Kim, Tae Sung ; O-Sullivan, InSug ; Martinez, Don ; Cohen, Edward P. / Combined therapy of an established, highly aggressive breast cancer in mice with paclitaxel and a unique DNA-based cell vaccine. In: International Journal of Cancer. 2006 ; Vol. 118, No. 11. pp. 2888-2898.
@article{118b5902da1944329a17a8bb11e32478,
title = "Combined therapy of an established, highly aggressive breast cancer in mice with paclitaxel and a unique DNA-based cell vaccine",
abstract = "Here, we describe the enhanced benefits of treating a highly aggressive breast cancer in mice with a combination of paclitaxel and immunization with a unique DNA-based cell vaccine. An adenocarcinoma was isolated from a spontaneous neoplasm that arose in the mammary gland of a C3H/He mouse (H-2k) (SB5b cells). The vaccine was prepared by transfer of genomic DNA-fragments (25 kb) from the breast cancer cells into a mouse fibroblast cell line (LM), modified to enhance its immunogenic properties. As the transferred DNA is integrated, and replicated as the recipient cells divide, the vaccine could be prepared from relatively small numbers of cancer cells (107 = 4 mm tumor). SB5b cells were injected into the mammary fat pad of na{\"i}ve C3H/He mice, which are highly susceptible to the growth of the cancer cells. When the tumors reached ∼3 mm, the mice were injected s.c. with a noncurative dose of paclitaxel. Six days later, when immune competence returned, the mice received the first of 3 weekly s.c. injections of the vaccine. The combined therapy induced robust cellular immunity to the breast cancer, mediated by CD8+ and NK/LAK cells, which resulted in prolonged survival. The immunity was specific, as immunization with a vaccine prepared by transfer of DNA from B16 melanoma cells into the fibroblasts failed to induce immunity to the breast cancer. This type of vaccine raises the possibility that an analogous strategy could be used in the treatment of breast cancer patients at an early stage of the disease.",
keywords = "Breast cancer, DNA-based cell vaccine, Immunotherapy, Preclinical",
author = "Amla Chopra and Kim, {Tae Sung} and InSug O-Sullivan and Don Martinez and Cohen, {Edward P.}",
year = "2006",
month = "6",
day = "1",
doi = "10.1002/ijc.21724",
language = "English",
volume = "118",
pages = "2888--2898",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - Combined therapy of an established, highly aggressive breast cancer in mice with paclitaxel and a unique DNA-based cell vaccine

AU - Chopra, Amla

AU - Kim, Tae Sung

AU - O-Sullivan, InSug

AU - Martinez, Don

AU - Cohen, Edward P.

PY - 2006/6/1

Y1 - 2006/6/1

N2 - Here, we describe the enhanced benefits of treating a highly aggressive breast cancer in mice with a combination of paclitaxel and immunization with a unique DNA-based cell vaccine. An adenocarcinoma was isolated from a spontaneous neoplasm that arose in the mammary gland of a C3H/He mouse (H-2k) (SB5b cells). The vaccine was prepared by transfer of genomic DNA-fragments (25 kb) from the breast cancer cells into a mouse fibroblast cell line (LM), modified to enhance its immunogenic properties. As the transferred DNA is integrated, and replicated as the recipient cells divide, the vaccine could be prepared from relatively small numbers of cancer cells (107 = 4 mm tumor). SB5b cells were injected into the mammary fat pad of naïve C3H/He mice, which are highly susceptible to the growth of the cancer cells. When the tumors reached ∼3 mm, the mice were injected s.c. with a noncurative dose of paclitaxel. Six days later, when immune competence returned, the mice received the first of 3 weekly s.c. injections of the vaccine. The combined therapy induced robust cellular immunity to the breast cancer, mediated by CD8+ and NK/LAK cells, which resulted in prolonged survival. The immunity was specific, as immunization with a vaccine prepared by transfer of DNA from B16 melanoma cells into the fibroblasts failed to induce immunity to the breast cancer. This type of vaccine raises the possibility that an analogous strategy could be used in the treatment of breast cancer patients at an early stage of the disease.

AB - Here, we describe the enhanced benefits of treating a highly aggressive breast cancer in mice with a combination of paclitaxel and immunization with a unique DNA-based cell vaccine. An adenocarcinoma was isolated from a spontaneous neoplasm that arose in the mammary gland of a C3H/He mouse (H-2k) (SB5b cells). The vaccine was prepared by transfer of genomic DNA-fragments (25 kb) from the breast cancer cells into a mouse fibroblast cell line (LM), modified to enhance its immunogenic properties. As the transferred DNA is integrated, and replicated as the recipient cells divide, the vaccine could be prepared from relatively small numbers of cancer cells (107 = 4 mm tumor). SB5b cells were injected into the mammary fat pad of naïve C3H/He mice, which are highly susceptible to the growth of the cancer cells. When the tumors reached ∼3 mm, the mice were injected s.c. with a noncurative dose of paclitaxel. Six days later, when immune competence returned, the mice received the first of 3 weekly s.c. injections of the vaccine. The combined therapy induced robust cellular immunity to the breast cancer, mediated by CD8+ and NK/LAK cells, which resulted in prolonged survival. The immunity was specific, as immunization with a vaccine prepared by transfer of DNA from B16 melanoma cells into the fibroblasts failed to induce immunity to the breast cancer. This type of vaccine raises the possibility that an analogous strategy could be used in the treatment of breast cancer patients at an early stage of the disease.

KW - Breast cancer

KW - DNA-based cell vaccine

KW - Immunotherapy

KW - Preclinical

UR - http://www.scopus.com/inward/record.url?scp=33646382107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646382107&partnerID=8YFLogxK

U2 - 10.1002/ijc.21724

DO - 10.1002/ijc.21724

M3 - Article

VL - 118

SP - 2888

EP - 2898

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 11

ER -